Andelyn Biosciences
1180 Arthur E. Adams Dr.
Columbus
OH
43221
United States
Tel: 614-580-8522
Website: https://andelynbio.com/
Email: careers@andelynbiosciences.com
About Andelyn Biosciences
Andelyn Biosciences is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. With 20+ years of experience manufacturing viral vectors, Andelyn's scientific expertise for development and characterization has led to GMP material being produced for over 75+ worldwide clinical trials and 400+ cGMP clinical batches. Advanced quality systems, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients. The name "Andelyn" is a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children's Hospital. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. "Andelyn" combines their names, representing all the families who have courageously participated in the research that make today's gene therapies possible. Continuing Andelyn's patient-based mission, the company is opening two state-of-the-art commercial manufacturing and development sites. The Dublin-based Andelyn Development Center is set to open in May 2022 and will house Andelyn's preclinical and development services. The 185,000 square foot Andelyn Corporate Center located on The Ohio State University's Innovation District will open for production in mid-2022.
Andelyn Biosciences is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™
8 articles about Andelyn Biosciences
-
Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency
3/25/2024
Andelyn Biosciences has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.
-
Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)
2/28/2024
Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies in its suspension platform for several programs under the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium.
-
Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasmid and Suspension AAV Vector Manufacturing and IND-enabling Studies from the National Institute of Neurological Disorders and Stroke (NINDS)
11/20/2023
Battelle, Andelyn Biosciences, Inc. , and AmplifyBio, have been awarded a new task order from the National Institute of Neurological Disorders and Stroke (NINDS) to manufacture suspension process gene therapy for the transformative treatment of Aspartylglucosaminuria (AGU).
-
Andelyn Biosciences and The Ohio State University Collaborate for Pre-clinical and GMP Manufacturing of Novel Gene Therapies
11/9/2023
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization, is collaborating with The Ohio State University Gene Therapy Institute for the development and clinical manufacturing of novel gene therapies.
-
Cell and Gene Therapy CDMO Andelyn Biosciences Celebrates Over 20 Years of Leadership and Innovation with Opening of New 180,000 Square Foot Manufacturing Headquarters
6/22/2023
Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center, located in the Innovation District in Columbus, Ohio.
-
Battelle, AmplifyBio, Andelyn Biosciences Win Research Contract for National Institute of Neurological Disorders and Stroke
1/6/2023
The team of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke.
-
FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development
1/13/2022
Andelyn Biosciences, a pioneering cell and gene therapy CDMO born out of Nationwide Children's Hospital, announced the U.S. FDA's acceptance of its GMP plasmid DNA drug master file, which enables the organization to vertically integrate its clients' manufacturing process, condensing timelines for developers to begin manufacturing to just three months.
-
Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing
8/25/2021
TetraScience announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers.